Jessie J. Hsu
University of California, Los Angeles(US)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Cutaneous Melanoma Detection and Management, Synthesis of Tetrazole Derivatives, Synthesis and biological activity, Ocular Oncology and Treatments
Most-Cited Works
- → Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial(2016)994 cited
- → Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis(2018)651 cited
- → A performance comparison study of ad hoc wireless multicast protocols(2002)480 cited
- → B-cell Lymphomas With Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms With Clinical and Pathologic Features Distinct From Burkitt Lymphoma and Diffuse Large B-cell Lymphoma(2010)354 cited
- → Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group(2008)322 cited
- → 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF V600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study(2021)174 cited
- → Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study(2017)99 cited
- → A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer(2017)59 cited
- → Performance of mobile ad hoc networking routing protocols in realistic scenarios(2004)55 cited
- → Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study(2017)44 cited